Vurchio, V.Valtorta, E.Lauricella, C.Annals of OncologyTrusolino L, Lonardi S, Bertotti A et al. Pertuzumab and trastuzumab-emtansine in HER2 positive metastatic colorectal cancer: the HERACLES B TRIAL. Poster presentation at 2016 AACR annual meeting, New Oleans April 16-20: Poster ...
To the Editor Huober and colleagues1 conducted an important analysis of a randomized clinical trial to assess if it is reasonable for patients to receive first-line pertuzumab plus trastuzumab alone (group A) vs with chemotherapy (group B) followed by trastuzumab and emtansine after progression. ...
Trastuzumab and pertuzumab plus metronomic oral cyclophosphamide, followed by trastuzumab emtansine after disease progression, might delay or supersede the need for taxane chemotherapy in this population.#F Hoffmann-La Roche. 展开 DOI: 10.1016/S1470-2045(18)30083-4 ...
were masked to treatment. Of 417 eligible patients, 107 were randomly assigned to group A, 107 to group B, 107 to group C, and 96 to group D. Patients given pertuzumab and trastuzumab plus docetaxel (group B) had a significantly improved pCR rate (49 of 107 patients; 45.8 % [95 % C...
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. NPJ Breast Cancer. 2022;8(1):106. Article CAS PubMed PubMed Central Google Scholar Cheng Y, Xiang H, Xin L, Duan X, Liu Y. Chinese Society of Breast Surgery ...
The PATRICIA study (NCT02536339) examined the efficacy and safety of pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) with progressive central nervous system (CNS) metastases following radiotherapy. Prim
The PATRICIA study (NCT02536339) examined the efficacy and safety of pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) with progressive central nervous system (CNS) metastases following radiotherapy. Prim
In a later study, DESTINY-Breast03 (NCT03529110), T-DXd was compared with trastuzumab emtansine (Kadcyla; T-DM1), another ADC, and demonstrated improved efficacy in terms of objective responses. The trial included 524 patients with HER2-positive mBC. The ORR observed...
Ado-trastuzumab (T-DM1), an antibody-drug conjugate of trastuzumab and a cytotoxic microtubule-inhibitory agent, emtansine, is approved in patients that have progressed with prior trastuzumab-based therapy. However, the benefit of T-DM1 in patie...
Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series The incidence of breast cancer brain metastasis (BCBM) is increasing due in part to improved management of systemic disease and prolonged survival. Despite... KC Keith,Y Lee,MG Ewend,... ...